"The evolution of the definition for high-risk multiple myeloma will help identify patients with light chain cast nephropathy, which is a key myeloma defining event for symptomatic multiple ...

Kidney dysfunction: In multiple myeloma, proteins known as free light chains build up in the kidneys, causing impaired function or "renal insufficiency." Signs include changes in urine frequency ...

Therapy-related B-lymphoblastic leukemia (B-ALL) following treatment for multiple myeloma is ... of B-ALL with surface kappa light chain expression post-myeloma treatment was made.

Genmab presents a long-term investment opportunity, but uncertainties around Darzalex's pending patent expiration warrant a ...

Johnson & Johnson is in pole position to bring a drug targeting GPRC5D to market as a new therapeutic approach to multiple myeloma ... cells and serum fee light chain biomarkers that indicate ...

Fresenius Medical Care offers strong credit, a solid pipeline, but weak margins and limited short-term upside curb enthusiasm ...

Not only are pharmaceutical stocks excellent defensive investments, some pharma stocks pay sizable dividends that can be a ...

Further investigation into CAR T-cell therapies for plasma cell disorders other than multiple myeloma is warranted. Historically, most rare plasma cell disorders like light chain amyloidosis (AL ...

Multiple myeloma is a type of blood cancer caused by a buildup of abnormal plasma cells in the bone marrow. As the abnormal ...